HomeEisai Co., Ltd.

Trade Eisai Co., Ltd. - 4523 CFD

Market is not available at the momentMarket information is presented
as of 2026-11-20T06:06:02+00:00
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread11.4
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
¥1,000
Overnight funding adjustment
Charges from full value of position
-0.01444 %
(-¥1)

Trade size with leverage ~ ¥10,000

Money from leverage ~ $¥9,000


-0.01444%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
¥1,000
Overnight funding adjustment
Charges from full value of position
-0.00778 %
(-¥1)

Trade size with leverage ~ ¥10,000

Money from leverage ~ $¥9,000


-0.00778%
Overnight funding adjustment time22:00 (UTC)
CurrencyJPY
Min traded quantity1
Margin10.00%
Stock exchangeJapan
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close5306.7
Open5288
1-Year Change12.5%
Day's Range5263.9 - 5349.4

Trade Eisai Co., Ltd. - 4523

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; BELVIQ for the treatment for chronic weight management; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which includes third-class OTC drugs, designated quasi-drugs, and food with nutrient function. Eisai Co., Ltd. has a collaboration agreement with Personal Genome Diagnostics Inc. to develop liquid biopsy biomarker discovery solution. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.

User feedback and ratings

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

1. Create your account2. Make your first deposit3. Start when you’re ready